Aro Biotherapeutics begins first human testing of its proprietary Centyrin technology platform

Aro Biotherapeutics, a Philadelphia biotechnology company founded five years ago to advance its proprietary technology for developing tissue-targeted genetic medicines, has initiated its first-ever human clinical trial.